Patent estate

Neurocrine Biosciences, Inc. — Patent Portfolio

1 drug with active patents · 16 active patents · 0 expired · 0 biologics with BPCIA exclusivity

AI-enriched 16/16 patents with grounded plain-English summaries · sourced from FDA Orange Book + Purple Book · updated 2026-05-18

§
Strategic Patent Estate Brief
AI-grounded executive summary · generated 2026-05-16

Verdict Neurocrine Biosciences, Inc. has a relatively weak patent estate with a high average vulnerability score, and faces a significant cliff year in 2035 with 1 drug losing exclusivity.

Portfolio overview Neurocrine Biosciences, Inc. has a total of 3 drugs in its portfolio, with 1 of them having patents. The company has a total of 16 US patents, all of which are active. The average vulnerability score of these patents is 75, indicating a relatively high risk of patent infringement. The patent estate is entirely vulnerable, with no ironclad patents.

Cliff calendar The company faces a significant cliff year in 2035, with 1 drug losing exclusivity. This includes Crenessity, which will lose exclusivity on January 21, 2035.

Most exposed drugs The top drug facing near-term loss of exclusivity is Crenessity, with an earliest active patent expiry date of January 21, 2035, an average vulnerability score of 75, and no annual revenue data available. This drug has 16 patents and is entirely vulnerable.

Biologic exclusivity Neurocrine Biosciences, Inc. has no biologics in its portfolio.

Strategic implications The company faces a total revenue at risk of $0 in the next 5 years. Given the weak patent estate and high vulnerability scores, the company may consider lifecycle moves such as subQ switches, label extensions, or combination filings to mitigate the risk of patent infringement and maintain revenue.

Sources: FDA Orange Book · FDA Purple Book · INPADOC family · USPTO · vulnerability scoring. Not legal advice.

Loss of exclusivity calendar · next 12 years

Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.

1 2035

Patent estate by drug

Crenessity (CRINECERFONT)

Cliff 2035 · 9y
Method of Use 16
  • US11311544 Vuln 75 2035-01-21
    This patent protects a method of using CRF1 receptor antagonists to treat congenital adrenal hyperplasia.
  • US11311544 Vuln 75 2035-01-21
    This patent protects a method of using CRF1 receptor antagonists to treat congenital adrenal hyperplasia.
  • US11730739 Vuln 75 2035-01-21
    This patent protects a method of using CRF1 receptor antagonists to treat congenital adrenal hyperplasia.
See all 16 patents →

Patent classification breakdown · active patents

By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.

  • Method of Use 16 patents

Sources

  • FDA Orange Book — small-molecule patents listed against approved NDAs.
  • FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
  • USPTO Patent Public Search — title, abstract, claim text grounding.
  • AI summaries generated by Drug Landscape, grounded in source claim text.

Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.

Track Neurocrine Biosciences, Inc.'s patent estate

Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.

↓ CSV export